Switch to:
Also traded in: Germany, Italy, Mexico, Spain, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.45
BAYRY's Cash-to-Debt is ranked lower than
74% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. BAYRY: 0.45 )
Ranked among companies with meaningful Cash-to-Debt only.
BAYRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: 0.29 Max: No Debt
Current: 0.45
Equity-to-Asset 0.37
BAYRY's Equity-to-Asset is ranked lower than
82% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. BAYRY: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
BAYRY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.23  Med: 0.36 Max: 0.48
Current: 0.37
0.23
0.48
Interest Coverage 9.94
BAYRY's Interest Coverage is ranked lower than
74% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. BAYRY: 9.94 )
Ranked among companies with meaningful Interest Coverage only.
BAYRY' s Interest Coverage Range Over the Past 10 Years
Min: 2.57  Med: 5.71 Max: N/A
Current: 9.94
Piotroski F-Score: 7
Altman Z-Score: 2.01
Beneish M-Score: -2.68
WACC vs ROIC
6.03%
12.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 13.72
BAYRY's Operating Margin % is ranked higher than
67% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. BAYRY: 13.72 )
Ranked among companies with meaningful Operating Margin % only.
BAYRY' s Operating Margin % Range Over the Past 10 Years
Min: 7.78  Med: 10.58 Max: 15.06
Current: 13.72
7.78
15.06
Net Margin % 9.67
BAYRY's Net Margin % is ranked higher than
62% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. BAYRY: 9.67 )
Ranked among companies with meaningful Net Margin % only.
BAYRY' s Net Margin % Range Over the Past 10 Years
Min: 3.71  Med: 7.35 Max: 14.55
Current: 9.67
3.71
14.55
ROE % 18.22
BAYRY's ROE % is ranked higher than
80% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. BAYRY: 18.22 )
Ranked among companies with meaningful ROE % only.
BAYRY' s ROE % Range Over the Past 10 Years
Min: 6.9  Med: 14.64 Max: 31.94
Current: 18.22
6.9
31.94
ROA % 5.89
BAYRY's ROA % is ranked higher than
62% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. BAYRY: 5.89 )
Ranked among companies with meaningful ROA % only.
BAYRY' s ROA % Range Over the Past 10 Years
Min: 2.54  Med: 5.19 Max: 8.78
Current: 5.89
2.54
8.78
ROC (Joel Greenblatt) % 31.07
BAYRY's ROC (Joel Greenblatt) % is ranked higher than
74% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. BAYRY: 31.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BAYRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.91  Med: 26.98 Max: 33.86
Current: 31.07
17.91
33.86
3-Year Revenue Growth Rate 5.00
BAYRY's 3-Year Revenue Growth Rate is ranked lower than
54% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. BAYRY: 5.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BAYRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.6  Med: 3 Max: 11.1
Current: 5
-10.6
11.1
3-Year EBITDA Growth Rate 13.00
BAYRY's 3-Year EBITDA Growth Rate is ranked higher than
57% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. BAYRY: 13.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BAYRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -9.9  Med: 3.7 Max: 15.4
Current: 13
-9.9
15.4
3-Year EPS without NRI Growth Rate 9.90
BAYRY's 3-Year EPS without NRI Growth Rate is ranked higher than
55% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. BAYRY: 9.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BAYRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -19.1  Med: 8.75 Max: 39.3
Current: 9.9
-19.1
39.3
GuruFocus has detected 5 Warning Signs with Bayer AG $BAYRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BAYRY's 10-Y Financials

Financials (Next Earnings Date: 2017-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BAYRY Guru Trades in Q1 2016

Ken Fisher 4,833,445 sh (+2.63%)
» More
Q2 2016

BAYRY Guru Trades in Q2 2016

Ken Fisher 4,909,612 sh (+1.58%)
» More
Q3 2016

BAYRY Guru Trades in Q3 2016

Ken Fisher 4,927,034 sh (+0.35%)
» More
Q4 2016

BAYRY Guru Trades in Q4 2016

Ken Fisher 4,859,655 sh (-1.37%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:LLY, NYSE:BMY, NYSE:ABBV, NYSE:AZN, OTCPK:GLAXF, NYSE:SNY, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, NYSE:MRK, OTCPK:OPHLY, OTCPK:NVSEF, OTCPK:KYKOF, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF, NAS:HCM, OTCPK:TGRNF, OTCPK:HAWPF » details
Traded in other countries:BAYA.Germany, BAY.Italy, BAYN N.Mexico, BAY.Spain, BAYN.Switzerland,
Headquarter Location:Germany
Bayer AG is engaged in the development, production and marketing of prescription Pharmaceutical. Its business segments are pharmaceutical, Consumer Health, Crop Science, Animal Health, and Covestro.

Bayer is a German healthcare and chemical conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and animal health products. The company has a crop science business that includes pesticides, herbicides, and fungicides, as well as a material science segment that produces plastics, including polyurethane and polycarbonate. However, the material science group will likely be divested.

Top Ranked Articles about Bayer AG

Monsanto Posts Profitable Quarter From South American Growth Company’s merger with Bayer remains on track
Monsanto Co. (NYSE:MON) posted strong first-quarter results for fiscal 2017 on Thursday, returning to profitability after battling a multiyear decline in the prices of corn, soybeans and other major crops. Read more...
Warren Buffett's Financial Engineering For decades Buffett used borrowed money and this strategy to crush the market
Investors often overlook the financial engineering that Warren Buffett (Trades, Portfolio) has employed throughout the years that helped build his personal fortune and the book value of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B). Read more...
Will the Monsanto-Bayer Deal Go Through? There are too many groups opposed to the merger
Bayer (BAYRY) has offered to buy Monsanto (NYSE:MON) for $128 a share, yet the market value of Monsanto is only $102.48. Evidently, the market does not think this deal is going to go through. Neither do I. Read more...
Monsanto Agrees to Bayer’s Proposal Merger would be largest foreign takeover by a German company
A proposed deal from Bayer (BAYRY) to buy Monsanto (NYSE:MON) was approved Wednesday. The deal will consolidate two of the world’s six agricultural giants. Read more...
Monsanto: What the Gurus May Be Telling Us About a Potential Buy-Out Analyzing the buying and selling of Monsanto shares to determine what 5 gurus expect from Bayer’s attempts to buy company
This week or next, a proposed deal in which Bayer AG (BAYRY) would buy the Monsanto Company (NYSE:MON) is expected to get the nod or get the boot. Read more...

Ratios

vs
industry
vs
history
PE Ratio 20.21
BAYRY's PE Ratio is ranked higher than
70% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.48 vs. BAYRY: 20.21 )
Ranked among companies with meaningful PE Ratio only.
BAYRY' s PE Ratio Range Over the Past 10 Years
Min: 8.9  Med: 23.2 Max: 37
Current: 20.21
8.9
37
Forward PE Ratio 13.72
BAYRY's Forward PE Ratio is ranked higher than
74% of the 202 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. BAYRY: 13.72 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.43
BAYRY's PE Ratio without NRI is ranked higher than
68% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.85 vs. BAYRY: 21.43 )
Ranked among companies with meaningful PE Ratio without NRI only.
BAYRY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.77  Med: 23.94 Max: 38.36
Current: 21.43
14.77
38.36
Price-to-Owner-Earnings 12.76
BAYRY's Price-to-Owner-Earnings is ranked higher than
86% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. BAYRY: 12.76 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BAYRY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.35  Med: 15.94 Max: 31.86
Current: 12.76
7.35
31.86
PB Ratio 2.98
BAYRY's PB Ratio is ranked higher than
51% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. BAYRY: 2.98 )
Ranked among companies with meaningful PB Ratio only.
BAYRY' s PB Ratio Range Over the Past 10 Years
Min: 1.54  Med: 2.64 Max: 5.55
Current: 2.98
1.54
5.55
PS Ratio 1.94
BAYRY's PS Ratio is ranked higher than
65% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. BAYRY: 1.94 )
Ranked among companies with meaningful PS Ratio only.
BAYRY' s PS Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.53 Max: 2.82
Current: 1.94
0.87
2.82
Price-to-Free-Cash-Flow 13.98
BAYRY's Price-to-Free-Cash-Flow is ranked higher than
74% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.83 vs. BAYRY: 13.98 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BAYRY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.27  Med: 19.61 Max: 248.88
Current: 13.98
7.27
248.88
Price-to-Operating-Cash-Flow 10.01
BAYRY's Price-to-Operating-Cash-Flow is ranked higher than
76% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. BAYRY: 10.01 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BAYRY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.51  Med: 9.83 Max: 19.39
Current: 10.01
5.51
19.39
EV-to-EBIT 16.43
BAYRY's EV-to-EBIT is ranked higher than
65% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. BAYRY: 16.43 )
Ranked among companies with meaningful EV-to-EBIT only.
BAYRY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 17.3 Max: 29.4
Current: 16.43
7.8
29.4
EV-to-EBITDA 10.27
BAYRY's EV-to-EBITDA is ranked higher than
78% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. BAYRY: 10.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAYRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.4  Med: 9.9 Max: 17.9
Current: 10.27
4.4
17.9
PEG Ratio 2.05
BAYRY's PEG Ratio is ranked lower than
54% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.90 vs. BAYRY: 2.05 )
Ranked among companies with meaningful PEG Ratio only.
BAYRY' s PEG Ratio Range Over the Past 10 Years
Min: 1.14  Med: 3.28 Max: 469.75
Current: 2.05
1.14
469.75
Shiller PE Ratio 28.86
BAYRY's Shiller PE Ratio is ranked higher than
71% of the 161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.67 vs. BAYRY: 28.86 )
Ranked among companies with meaningful Shiller PE Ratio only.
BAYRY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.21  Med: 30.92 Max: 46.41
Current: 28.86
19.21
46.41
Current Ratio 1.64
BAYRY's Current Ratio is ranked lower than
70% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. BAYRY: 1.64 )
Ranked among companies with meaningful Current Ratio only.
BAYRY' s Current Ratio Range Over the Past 10 Years
Min: 1.24  Med: 1.57 Max: 2.21
Current: 1.64
1.24
2.21
Quick Ratio 1.19
BAYRY's Quick Ratio is ranked lower than
71% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. BAYRY: 1.19 )
Ranked among companies with meaningful Quick Ratio only.
BAYRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 1.02 Max: 1.48
Current: 1.19
0.76
1.48
Days Inventory 151.30
BAYRY's Days Inventory is ranked lower than
67% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. BAYRY: 151.30 )
Ranked among companies with meaningful Days Inventory only.
BAYRY' s Days Inventory Range Over the Past 10 Years
Min: 126.65  Med: 140.55 Max: 154.01
Current: 151.3
126.65
154.01
Days Sales Outstanding 85.45
BAYRY's Days Sales Outstanding is ranked lower than
58% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. BAYRY: 85.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAYRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.71  Med: 69.96 Max: 85.61
Current: 85.45
65.71
85.61
Days Payable 115.04
BAYRY's Days Payable is ranked higher than
74% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. BAYRY: 115.04 )
Ranked among companies with meaningful Days Payable only.
BAYRY' s Days Payable Range Over the Past 10 Years
Min: 54.65  Med: 79.63 Max: 115.28
Current: 115.04
54.65
115.28

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.44
BAYRY's Dividend Yield % is ranked higher than
70% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. BAYRY: 2.44 )
Ranked among companies with meaningful Dividend Yield % only.
BAYRY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.44  Med: 2.4 Max: 3.93
Current: 2.44
1.44
3.93
Dividend Payout Ratio 0.49
BAYRY's Dividend Payout Ratio is ranked lower than
67% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. BAYRY: 0.49 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BAYRY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.36  Med: 0.51 Max: 0.89
Current: 0.49
0.36
0.89
3-Year Dividend Growth Rate 9.60
BAYRY's 3-Year Dividend Growth Rate is ranked higher than
54% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. BAYRY: 9.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BAYRY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.6 Max: 34.9
Current: 9.6
0
34.9
Forward Dividend Yield % 2.54
BAYRY's Forward Dividend Yield % is ranked higher than
70% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. BAYRY: 2.54 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.07
BAYRY's 5-Year Yield-on-Cost % is ranked higher than
80% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. BAYRY: 4.07 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BAYRY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.4  Med: 4.01 Max: 6.56
Current: 4.07
2.4
6.56

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 200.08
BAYRY's Price-to-Tangible-Book is ranked lower than
99% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. BAYRY: 200.08 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BAYRY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.19  Med: 3.67 Max: 200.08
Current: 200.08
2.19
200.08
Price-to-Intrinsic-Value-Projected-FCF 1.40
BAYRY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. BAYRY: 1.40 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BAYRY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.8  Med: 1.52 Max: 3.1
Current: 1.4
0.8
3.1
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.27
BAYRY's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
51% of the 80 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.33 vs. BAYRY: 1.27 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.27
BAYRY's Price-to-Median-PS-Value is ranked lower than
65% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. BAYRY: 1.27 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BAYRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 0.85 Max: 1.84
Current: 1.27
0.34
1.84
Price-to-Peter-Lynch-Fair-Value 2.28
BAYRY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
68% of the 174 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. BAYRY: 2.28 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BAYRY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.75  Med: 2 Max: 5.7
Current: 2.28
0.75
5.7
Price-to-Graham-Number 13.79
BAYRY's Price-to-Graham-Number is ranked lower than
98% of the 408 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. BAYRY: 13.79 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BAYRY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.2  Med: 2 Max: 13.79
Current: 13.79
1.2
13.79
Earnings Yield (Greenblatt) % 6.09
BAYRY's Earnings Yield (Greenblatt) % is ranked higher than
74% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. BAYRY: 6.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BAYRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.4  Med: 5.8 Max: 12.9
Current: 6.09
3.4
12.9
Forward Rate of Return (Yacktman) % 13.82
BAYRY's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.72 vs. BAYRY: 13.82 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BAYRY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8.5  Med: 10.4 Max: 26.4
Current: 13.82
-8.5
26.4

More Statistics

Revenue (TTM) (Mil) $51,701
EPS (TTM) $ 6.06
Beta1.09
Short Percentage of Float0.01%
52-Week Range $91.53 - 124.26
Shares Outstanding (Mil)826.95

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 52,235 61,293 56,921
EPS ($) 8.16 8.80 9.34
EPS without NRI ($) 8.16 8.80 9.34
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.27%
Dividends per Share ($) 2.91 3.05 3.28
» More Articles for BAYRY

Headlines

Articles On GuruFocus.com
Monsanto CEO Pares Position in Company Apr 12 2017 
2 Arbitrage Ideas From Warren Buffett and Seth Klarman Feb 23 2017 
A Green Light on Bayer Jan 19 2017 
Monsanto Posts Profitable Quarter From South American Growth Jan 06 2017 
A Year in Review and Recommendations for 2017 Dec 27 2016 
Warren Buffett's Financial Engineering Nov 15 2016 
3 Chemical Companies From Polaris Global Value Oct 17 2016 
Will the Monsanto-Bayer Deal Go Through? Sep 20 2016 
Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap Sep 19 2016 
Monsanto Agrees to Bayer’s Proposal Sep 15 2016 

More From Other Websites
J&J, Bayer Accused of Hiding Blood-Thinning Drug's Flaws Apr 24 2017
United Airlines Doesn't Look So Bad Next to These 5 Companies Apr 13 2017
OncoMed Cancer Candidate Fails Trial, Bayer Opts Out of Deal Apr 11 2017
OncoMed Cancer Drug Fails, Loses Bayer Partnership Apr 10 2017
Monsanto's (MON) Prospects Look Bright on Solid Q2 Earnings Apr 10 2017
Monsanto CEO: Our Bayer deal is unique Apr 06 2017
Monsanto second-quarter profit jumps on strong demand for seeds Apr 05 2017
Monsanto CEO: Why consolidation is good for agtech Apr 05 2017
Monsanto (MON) Tops Q2 Earnings, Updates FY17 EPS Outlook Apr 05 2017
Monsanto (MON) Beats on Q2 Earnings & Revenues Apr 05 2017
Bayer Announced Positive Data for Cancer Drug Copanlisib Apr 03 2017
Top Research Reports for Vale, ConocoPhillips & Colgate-Palmolive Mar 30 2017
Drug Launches, Diversity Support Bayer's Steady Gains Mar 29 2017
Syngenta interested in assets from Bayer, Monsanto deal Mar 28 2017
Why Monsanto (MON) is a Must-Add Stock to Your Portfolio? Mar 28 2017
Dow-DuPont Deal Wins Conditional Antitrust Approval From EU Mar 27 2017
Roche Restructuring Shows Trouble in US Diabetes Biz Mar 17 2017
Bayer Heroin, Coca-Cola’s Cocaine, and Mrs. Winslow’s Soothing Syrup: Is Sugar More Addictive... Mar 16 2017
CRISPR to Use MaxCyte Cell Engineering Platform Mar 14 2017
Bayer, Monsanto start $2.5 billion asset sale to get merger clearance: sources Mar 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)